Atlas Capital Advisors LLC Grows Stock Holdings in CVS Health Co. (NYSE:CVS)

Atlas Capital Advisors LLC boosted its holdings in CVS Health Co. (NYSE:CVS) by 20.2% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 5,101 shares of the pharmacy operator’s stock after buying an additional 858 shares during the period. Atlas Capital Advisors LLC’s holdings in CVS Health were worth $407,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Riverpoint Wealth Management Holdings LLC purchased a new position in shares of CVS Health during the fourth quarter valued at about $218,000. Canoe Financial LP increased its stake in CVS Health by 95.1% in the 4th quarter. Canoe Financial LP now owns 1,762,629 shares of the pharmacy operator’s stock worth $139,177,000 after acquiring an additional 859,134 shares during the last quarter. Meritage Portfolio Management boosted its position in shares of CVS Health by 30.6% during the 4th quarter. Meritage Portfolio Management now owns 66,322 shares of the pharmacy operator’s stock valued at $5,237,000 after acquiring an additional 15,548 shares during the last quarter. Ancora Advisors LLC grew its holdings in shares of CVS Health by 17.5% in the third quarter. Ancora Advisors LLC now owns 457,267 shares of the pharmacy operator’s stock valued at $31,926,000 after purchasing an additional 68,005 shares in the last quarter. Finally, Steph & Co. increased its position in CVS Health by 192.0% in the first quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock worth $35,000 after purchasing an additional 288 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on CVS shares. Argus dropped their price objective on shares of CVS Health from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Robert W. Baird assumed coverage on CVS Health in a research note on Thursday, May 30th. They set a “neutral” rating and a $61.00 price objective on the stock. Baird R W raised CVS Health to a “hold” rating in a research note on Thursday, May 30th. The Goldman Sachs Group cut their target price on CVS Health from $85.00 to $74.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of CVS Health from $101.00 to $86.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Eleven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.05.

Insider Activity at CVS Health

In other news, Director Edward J. Ludwig purchased 1,000 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were acquired at an average cost of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.24% of the stock is currently owned by corporate insiders.

CVS Health Price Performance

NYSE CVS opened at $58.37 on Friday. The company has a market cap of $73.27 billion, a PE ratio of 10.26, a P/E/G ratio of 0.58 and a beta of 0.53. CVS Health Co. has a 52-week low of $52.77 and a 52-week high of $83.25. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. The firm’s 50 day moving average price is $60.00 and its 200-day moving average price is $70.38.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The company had revenue of $88.44 billion during the quarter, compared to analysts’ expectations of $89.33 billion. During the same quarter in the prior year, the business posted $2.20 earnings per share. The company’s revenue was up 3.7% compared to the same quarter last year. Sell-side analysts forecast that CVS Health Co. will post 7.02 EPS for the current fiscal year.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.